response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients [published online November 28, 2018]. J Clin Psychol. 2018. doi: 10.1002/jclp.22725.
Advertisement
Articles by response to treatment in an adherence intervention trial for relapsing-remitting multiple sclerosis patients [published online November 28, 2018]. J Clin Psychol. 2018. doi: 10.1002/jclp.22725.
Advertisement
Latest Updated Articles
- Exploring Novel Reasons for Nonadherence to Disease-Modifying Therapies
Published: January 26th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5
